[go: up one dir, main page]

BR9712955A - Peptìdio derivado de um antìgeno reconhecido por auto-anticorpos de pacientes com artrite reumatóide, anticorpo direcionado contra o dito peptìdeo, antìgeno combinatório e método de detecção de anticorpos auto-imunes - Google Patents

Peptìdio derivado de um antìgeno reconhecido por auto-anticorpos de pacientes com artrite reumatóide, anticorpo direcionado contra o dito peptìdeo, antìgeno combinatório e método de detecção de anticorpos auto-imunes

Info

Publication number
BR9712955A
BR9712955A BR9712955-0A BR9712955A BR9712955A BR 9712955 A BR9712955 A BR 9712955A BR 9712955 A BR9712955 A BR 9712955A BR 9712955 A BR9712955 A BR 9712955A
Authority
BR
Brazil
Prior art keywords
peptide
antigen
autoantibodies
rheumatoid arthritis
patients
Prior art date
Application number
BR9712955-0A
Other languages
English (en)
Inventor
Waltherus Jacobus Wil Venrooij
Gerardus Antonius Schellekens
Jozef Maria Hendrik Raats
Rene Michael Antonius Hoet
Original Assignee
Stichting Scheikundig Onderzoe
Stichting Vdor De Tech Wetensc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19763876&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9712955(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stichting Scheikundig Onderzoe, Stichting Vdor De Tech Wetensc filed Critical Stichting Scheikundig Onderzoe
Publication of BR9712955A publication Critical patent/BR9712955A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patente de Invenção:<B>"PEPTìDIO DERIVADO DE UM ANTìGENO RECONHECIDO POR AUTO-ANTICORPOS DE PACIENTES COM ARTRITE REUMATóIDE, ANTICORPO DIRECIONADO CONTRA O DITO PEPTìDIO, ANTìGENO COMBINATóRIO E MéTODO DE DETECçãO DE ANTICORPOS AUTO-IMUNES"<D>. A invenção refere-se a um peptídio derivado de um antígeno reconhecido por anticorpos, cujo peptídio é reativo com anticorpos auto-imunes de um paciente sofrendo de artrite reumatóide. O peptídio de acordo com a invenção possui um resíduo de arginina modificado. A invenção também refere-se a anticorpos contra o peptídio e um método de detecção de anticorpos auto-imunes.
BR9712955-0A 1996-11-15 1997-11-14 Peptìdio derivado de um antìgeno reconhecido por auto-anticorpos de pacientes com artrite reumatóide, anticorpo direcionado contra o dito peptìdeo, antìgeno combinatório e método de detecção de anticorpos auto-imunes BR9712955A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1004539A NL1004539C2 (nl) 1996-11-15 1996-11-15 Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
PCT/NL1997/000624 WO1998022503A2 (en) 1996-11-15 1997-11-14 Peptide derived from an antigen recognized by autoantibodies from patients with rheumatoid arthritis, antibody directed against said peptide, a combinatorial antigen, and a method of detecting auto-immune antibodies

Publications (1)

Publication Number Publication Date
BR9712955A true BR9712955A (pt) 1999-12-07

Family

ID=19763876

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712955-0A BR9712955A (pt) 1996-11-15 1997-11-14 Peptìdio derivado de um antìgeno reconhecido por auto-anticorpos de pacientes com artrite reumatóide, anticorpo direcionado contra o dito peptìdeo, antìgeno combinatório e método de detecção de anticorpos auto-imunes

Country Status (13)

Country Link
US (5) US6858438B2 (pt)
EP (1) EP0941244B1 (pt)
JP (1) JP4197743B2 (pt)
AT (1) ATE352560T1 (pt)
AU (1) AU741850B2 (pt)
BR (1) BR9712955A (pt)
CA (1) CA2272573C (pt)
DE (1) DE69737292T2 (pt)
DK (1) DK0941244T3 (pt)
ES (1) ES2281095T3 (pt)
NL (1) NL1004539C2 (pt)
PT (1) PT941244E (pt)
WO (1) WO1998022503A2 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004539C2 (nl) * 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
AU2155899A (en) * 1997-11-28 1999-06-16 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
FR2773078B1 (fr) * 1997-12-30 2000-05-26 Univ Toulouse Utilisation de peptides citrullines derives de la filaggrine pour le traitement de la polyarthrite rhumatoide
FR2795735B1 (fr) 1999-07-01 2001-09-07 Univ Toulouse Derives citrullines de la fibrine et leur utilisation pour le diagnostic ou le traitement de la polyarthrite rhumatoide
EP1240180A2 (en) * 1999-12-21 2002-09-18 Innogenetics N.V. Peptides designed for the diagnosis and treatment of rheumatoid arthritis
NL1019540C2 (nl) * 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit.
AU2004222345A1 (en) * 2003-03-14 2004-09-30 Ppd Biomarker Discovery Sciences, Llc Biological markers for diagnosing rheumatoid arthritis
ES2340328T3 (es) 2003-12-23 2010-06-01 F. Hoffmann-La Roche Ag Metodo para la evaluacion de la artritis reumatoide mediante la medicion de anti-pcc e interleuquina 6.
PL1721162T3 (pl) 2004-02-27 2009-03-31 Hoffmann La Roche Sposób oceny reumatoidalnego zapalenia stawów przez pomiar anty-CCP oraz amyloidu A w surowicy
US20060141547A1 (en) * 2004-11-16 2006-06-29 Das Hasi R Novel diagnostic marker, a diagnostic kit and a method for diagnosis of rheumatoid arthritis
JP2010506147A (ja) 2006-09-29 2010-02-25 エフ．ホフマン−ラ ロシュ アーゲー 関節リウマチを有する患者のための疾患進行のリスク評価
ES2307421B1 (es) * 2007-04-30 2009-09-28 Consejo Superiorde Investigaciones Cientificas (Csic) Polipeptido quimerico fibrina-filagrina citruinado capaz de detectar los anticuerpos generados en la artritis reumatoide.
US8323656B2 (en) * 2007-06-25 2012-12-04 Yijun Xu Antigen determinant of rheumatoid arthritis-specific autoantibody and use thereof
ES2390394T3 (es) 2007-12-03 2012-11-12 Sqi Diagnostics Systems Inc. Péptidos sintéticos inmunorreactivos con los autoanticuerpos de la artritis reumatoide
RU2386609C2 (ru) * 2008-01-22 2010-04-20 Общество с ограниченной ответственностью "Филагр" Иммунореактивный пептид и способ диагностики ревматоидного артрита с его использованием
GB0803107D0 (en) * 2008-02-20 2008-03-26 Axis Shield Diagnostics Ltd Method
ES2584438T3 (es) 2008-03-21 2016-09-27 Universiteit Hasselt Biomarcadores para artritis reumatoide
NO2294086T3 (pt) * 2008-06-04 2018-02-10
EP2204655A1 (en) 2008-12-23 2010-07-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnostic prediction of rheumatoid arthritis and systemic lupus erythematosus
EP2325195A1 (en) 2009-11-23 2011-05-25 Toscana Biomarkers S.r.l. Viral citrullinated peptides and uses thereof
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
EP2336769A1 (en) 2009-12-18 2011-06-22 F. Hoffmann-La Roche AG Trigger assay for differentiating between rheumatic and non-rheumatic disorders
EP2402368A1 (en) 2010-07-02 2012-01-04 Toscana Biomarkers S.r.l. Histone citrullinated peptides and uses thereof
RU2013130324A (ru) * 2011-01-10 2015-02-20 ОПКО Фармасьютикалз, ЛЛС Суррогаты антигенов при аутоиммунных заболеваниях
EP2527841A1 (en) 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Methods for the diagnosis of rheumatoid arthritis
WO2013014312A1 (es) * 2011-07-28 2013-01-31 Consejo Superior De Investigaciones Científicas (Csic) Polipeptidos quimericos derivados de la proteina vimentina con utilidad para el diagnostico de la artritis reumatoide
WO2016128348A1 (en) 2015-02-13 2016-08-18 F. Hoffmann-La Roche Ag Method of assessing rheumatoid arthritis by measuring anti-ccp and anti-pik3cd
EP3056903A1 (en) 2015-02-13 2016-08-17 F. Hoffmann-La Roche AG Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-Casp8
EP3056904A1 (en) 2015-02-13 2016-08-17 F. Hoffmann-La Roche AG Method of assessing rheumatoid arthritis by measuring anti-CCP and anti-MCM3
KR101758354B1 (ko) * 2015-03-26 2017-07-17 한국과학기술연구원 신규한 시클릭 시트룰리네이티드 펩티드, 이를 포함하는 류마티스 관절염 진단용 조성물 및 이를 이용한 진단 방법, 및 류마티스 관절염 마커 스크리닝 방법
CN108196073B (zh) * 2018-03-13 2019-09-13 江苏浩欧博生物医药股份有限公司 一种测定抗环瓜氨酸肽抗体的试剂盒及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE511116T1 (de) * 1991-04-26 1993-04-29 Clonatec S.A., Paris Antigene, die von polyarthritis rheumatoide antikoerpern erkannt werden, ihre herstellung und ihre anwendungen.
US6100377A (en) * 1994-06-10 2000-08-08 The Trustees Of The University Of Pennsylvania Constrained peptides
FR2752842B1 (fr) 1996-08-30 1998-11-06 Biomerieux Sa Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide
NL1004539C2 (nl) * 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
FR2773405B1 (fr) * 1998-01-08 2000-09-29 France Telecom Procede et systeme de controle d'acces a une ressource limite a certaines plages horaires

Also Published As

Publication number Publication date
US6858438B2 (en) 2005-02-22
US20060039924A1 (en) 2006-02-23
ES2281095T3 (es) 2007-09-16
EP0941244B1 (en) 2007-01-24
US20140342378A1 (en) 2014-11-20
US7288634B2 (en) 2007-10-30
EP0941244A2 (en) 1999-09-15
US20080050841A1 (en) 2008-02-28
ATE352560T1 (de) 2007-02-15
DE69737292T2 (de) 2007-06-28
WO1998022503A3 (en) 1998-08-27
US8772448B2 (en) 2014-07-08
AU4970797A (en) 1998-06-10
JP2001513753A (ja) 2001-09-04
DK0941244T3 (da) 2007-04-30
AU741850B2 (en) 2001-12-13
US20050186201A1 (en) 2005-08-25
NL1004539C2 (nl) 1998-05-20
JP4197743B2 (ja) 2008-12-17
US20020137092A1 (en) 2002-09-26
US7335724B2 (en) 2008-02-26
WO1998022503A2 (en) 1998-05-28
CA2272573C (en) 2010-02-02
DE69737292D1 (de) 2007-03-15
PT941244E (pt) 2007-02-28
CA2272573A1 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
BR9712955A (pt) Peptìdio derivado de um antìgeno reconhecido por auto-anticorpos de pacientes com artrite reumatóide, anticorpo direcionado contra o dito peptìdeo, antìgeno combinatório e método de detecção de anticorpos auto-imunes
Burkhardt et al. Humoral immune response to citrullinated collagen type II determinants in early rheumatoid arthritis
ES2108460T3 (es) Fragmentos de anticuerpos en terapeutica.
PT1456662E (pt) Deteccao de auto-anticorpos de pacientes que sofrem de artrite reumatoide
ES2152306T3 (es) Anticuerpos monoclonales reactivos con regiones definidas del receptor del antigeno de la celula t.
DE69133179D1 (de) Katalytische antikörperkomponente
DE60034564D1 (de) Menschlicher cytokinrezeptor
ES2167590T3 (es) Metodo para diagnosticar enfermedades autoinmunes.
ATE442439T1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
WO2004020456A3 (en) Selecting therapeutic human monoclonal antibodies from disease-specific libraries
DE69615576D1 (de) Polyklonaler antikörper gegen tryptase und reinigungsverfahren zur verwendung in einem immunoassay für menschliche tryptase
EP0585960A3 (en) Diagnostic method for autoimmune diseases
FI103975B1 (fi) Immunodiagnostinen nivelreumakoe
AU2002363465A8 (en) Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
DK0785274T3 (da) Kunstigt rekombinant substrat (rAGG-1) og nativ aggrecan til undersøgelse af den proteolytiske aktivitet af &#34;aggrecanase&#34; i
EP1094080A3 (en) Anti-dnase-gamma antibody, and production and use thereof
ATE192236T1 (de) Menschliche phospholipase aktivierender proteinteil
SE9602234D0 (sv) A novel diagnostic method utilizing ECP, and reagents to be used in the methods
DK0583352T3 (da) hGPIIB fragmenter og deres anvendelse i in vitro metoder til bestemmelse af in vivo thrombotiske tilstande
DE69333683D1 (de) Antikörper-testbesteck zur bestimmung von amylin
SE9900875D0 (sv) Antinuclear antibody assay utilizing stress-treated cells or cell extracts
DE69829285D1 (de) Diagnose von autoimmun-nebennierenkrankheit
DK1041997T3 (da) Anvendelse af citrullinerede peptider afledt af filaggrin til behandling af autoimmunsygdomme
ES2136534A1 (es) Uso de la cd-1 sacalina para la deteccion y seguimiento de la enfermedad celiaca.
UA36086A (uk) Тест-система для підтвердження наявності антитіл проти вірусу гепатиту с (іфа-п-hcv)

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL)

Free format text: TRANSFERIDO DE: STICHTING SCHEIKUNDIG ONDERZOEK IN NEDERLAND (SON)

B25G Requested change of headquarter approved

Owner name: STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL)

Free format text: ALTERADA A SEDE DO TITULAR CONFORME SOLICITADO NA PETICAO NO 048244/RJ DE 23/08/2004.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 37, INDEFIRO O PRESENTE PEDIDO, UMA VEZ QUE: -AS REIVINDICACOES 1, 3 E 7 NAO APRESENTAM SUFICIENCIA DESCRITIVA (ART. 24 DA LPI), E NAO HOUVE CUMPRIMENTO DA EXIGENCIA TECNICA DE INCORPORACAO DA MATERIA DA REIVINDICACAO 2 A MATERIA DA REIVINDICACAO 1; -AS REIVINDICACOES 4-6 NAO APRESENTAM SUFICIENCIA DESCRITIVA (ART. 24 DA LPI); -A REIVINDICACAO 8 NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA (ART. 8O COMBINADO COM O ART. 13 DA LPI)